Biotech Values

[drbio45]

Medicure to Host Analyst & Investor Day
Tuesday November 7, 7:00 am ET

http://biz.yahoo.com/iw/061107/0181187.html

If you want a cheap stock that is very undervalued, my opinion anyway, listen to the analyst day webcast.

WINNIPEG, MANITOBA--(MARKET WIRE)--Nov 7, 2006 -- Medicure Inc. (TSX:MPH.TO - News)(AMEX:MCU - News), a cardiovascular focused biopharmaceutical company, today announced it will host an Analyst & Investor Day at 12:00 PM Eastern on Friday, November 17, 2006 in the Metropolitan Suite of the Four Seasons Hotel in New York City. The aim of the presentations is to provide institutional investors and analysts with a clinical and therapeutic update on Medicure's acute cardiovascular products, MC-1 and AGGRASTAT(r). Presentations will be made by the Company's senior management and cardiovascular opinion leaders, including:
- Dr. Paul W. Armstrong, MD ,FRCP©,FACC, Professor of Medicine, Division of Cardiology, Director Canadian VIGOUR Centre, University of Alberta, Chair, Medicure's Scientific Advisory Board

- Christopher B. Granger, MD, Associate Professor of Medicine, Director, Cardiac Care Unit, Co-Director, Cardiovascular Clinical Trials, Duke University Medical Center, Duke Clinical Research Institute

- Harvey D. White, MB, ChB, DSc, Professor of Medicine, University of Auckland, New Zealand, Director, Coronary Care and Cardiovascular Research, Green Lane Hospital & Auckland City Hospital

To register to attend, please contact Hogan Mullally of Medicure at [e-mail] or Lee Stern of the Trout Group at [e-mail]. The presentation will be made available by webcast and can be accessed on the Investor Relations page of the Medicure website at www.medicure.com.

ADVERTISEMENT


About Medicure Inc.

Medicure is a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders. The Company's solid position in this field is highlighted by the following:

- Two drugs, MC-1 & MC-4232, in late stage clinical development

- Four positive Phase II trials completed with MC-1

- FDA Fast Track designation for MC-1

- U.S. rights to AGGRASTAT® Injection (tirofiban hydrochloride)

- Dual action antithrombotic, MC-45308, with positive preclinical results

Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies.